BioDelivery Sciences International (NASDAQ:BDSI) had its price target lifted by investment analysts at LADENBURG THALM/SH SH from $6.00 to $8.00 in a research note issued on Wednesday, The Fly reports. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. LADENBURG THALM/SH SH’s target price would suggest a potential upside of 33.33% from the stock’s current price.
Several other research firms also recently commented on BDSI. William Blair reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a report on Tuesday, September 17th. BidaskClub downgraded shares of BioDelivery Sciences International from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. ValuEngine raised shares of BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 29th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a report on Wednesday. One analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $6.50.
BioDelivery Sciences International stock traded up $0.15 during mid-day trading on Wednesday, reaching $6.00. 3,554,700 shares of the company traded hands, compared to its average volume of 905,762. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.34 and a quick ratio of 2.09. BioDelivery Sciences International has a fifty-two week low of $2.80 and a fifty-two week high of $6.45. The company has a market capitalization of $518.34 million, a price-to-earnings ratio of -8.22 and a beta of 0.39. The firm’s fifty day moving average is $5.15 and its two-hundred day moving average is $4.58.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.34. The business had revenue of $30.31 million for the quarter, compared to the consensus estimate of $28.86 million. BioDelivery Sciences International had a negative net margin of 34.73% and a negative return on equity of 0.85%. As a group, equities research analysts predict that BioDelivery Sciences International will post -0.05 earnings per share for the current year.
In other news, Director Mark A. Sirgo sold 157,177 shares of the company’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $4.79, for a total value of $752,877.83. Following the sale, the director now directly owns 1,874,637 shares of the company’s stock, valued at approximately $8,979,511.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $4.29, for a total transaction of $34,320.00. Following the completion of the sale, the director now directly owns 588,754 shares in the company, valued at $2,525,754.66. The disclosure for this sale can be found here. Insiders sold a total of 373,364 shares of company stock worth $1,859,559 over the last ninety days. Insiders own 8.94% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. NEXT Financial Group Inc boosted its position in BioDelivery Sciences International by 17.0% in the 2nd quarter. NEXT Financial Group Inc now owns 135,350 shares of the specialty pharmaceutical company’s stock valued at $629,000 after buying an additional 19,700 shares during the period. BTR Capital Management Inc. purchased a new stake in BioDelivery Sciences International in the 2nd quarter valued at about $47,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in BioDelivery Sciences International in the 2nd quarter valued at about $1,395,000. Cutter & CO Brokerage Inc. purchased a new stake in BioDelivery Sciences International in the 2nd quarter valued at about $60,000. Finally, Emerald Advisers LLC boosted its position in BioDelivery Sciences International by 7.9% in the 2nd quarter. Emerald Advisers LLC now owns 1,872,132 shares of the specialty pharmaceutical company’s stock valued at $8,705,000 after buying an additional 137,710 shares during the period. 66.89% of the stock is currently owned by hedge funds and other institutional investors.
BioDelivery Sciences International Company Profile
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Featured Story: Stocks Increasing Dividends
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.